DE1923336A1 - Arzneimittel zur Behandlung von entzuendlichen Affektionen,Algien und Verletzungen - Google Patents
Arzneimittel zur Behandlung von entzuendlichen Affektionen,Algien und VerletzungenInfo
- Publication number
- DE1923336A1 DE1923336A1 DE19691923336 DE1923336A DE1923336A1 DE 1923336 A1 DE1923336 A1 DE 1923336A1 DE 19691923336 DE19691923336 DE 19691923336 DE 1923336 A DE1923336 A DE 1923336A DE 1923336 A1 DE1923336 A1 DE 1923336A1
- Authority
- DE
- Germany
- Prior art keywords
- treatment
- algias
- injuries
- thiobenzimidazole
- inflammatory diseases
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims description 10
- 241001237754 Algia Species 0.000 title claims description 8
- 230000006378 damage Effects 0.000 title claims description 7
- 229940079593 drug Drugs 0.000 title claims description 3
- 208000027866 inflammatory disease Diseases 0.000 title claims 3
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 9
- 239000002253 acid Substances 0.000 claims description 7
- 150000007513 acids Chemical class 0.000 claims description 6
- 229910052500 inorganic mineral Chemical class 0.000 claims description 5
- 239000011707 mineral Chemical class 0.000 claims description 5
- 150000007524 organic acids Chemical class 0.000 claims description 4
- 235000005985 organic acids Nutrition 0.000 claims description 4
- 239000000829 suppository Substances 0.000 claims description 4
- 239000002674 ointment Substances 0.000 claims description 3
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 2
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 230000002757 inflammatory effect Effects 0.000 description 5
- 208000014674 injury Diseases 0.000 description 5
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- QGJOPFRUJISHPQ-UHFFFAOYSA-N Carbon disulfide Chemical compound S=C=S QGJOPFRUJISHPQ-UHFFFAOYSA-N 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229920001525 carrageenan Polymers 0.000 description 3
- 235000010418 carrageenan Nutrition 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 125000005456 glyceride group Chemical group 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- -1 OaIcum Substances 0.000 description 1
- 206010034464 Periarthritis Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 208000008765 Sciatica Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 241000906446 Theraps Species 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 229940058303 antinematodal benzimidazole derivative Drugs 0.000 description 1
- 150000001556 benzimidazoles Chemical class 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000009519 contusion Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000007897 gelcap Substances 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 150000003217 pyrazoles Chemical class 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 150000003873 salicylate salts Chemical class 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/28—Sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR151010 | 1968-05-08 | ||
| FR160292A FR7716M (enrdf_load_stackoverflow) | 1968-07-23 | 1968-07-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE1923336A1 true DE1923336A1 (de) | 1969-11-20 |
Family
ID=26181992
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19691923336 Pending DE1923336A1 (de) | 1968-05-08 | 1969-05-07 | Arzneimittel zur Behandlung von entzuendlichen Affektionen,Algien und Verletzungen |
Country Status (4)
| Country | Link |
|---|---|
| BE (1) | BE732508A (enrdf_load_stackoverflow) |
| DE (1) | DE1923336A1 (enrdf_load_stackoverflow) |
| GB (1) | GB1217138A (enrdf_load_stackoverflow) |
| NL (1) | NL6906963A (enrdf_load_stackoverflow) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0064830A3 (en) * | 1981-04-29 | 1983-08-10 | Pfizer Limited | Pharmaceutical compositions for treating nail infections |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4728741A (en) * | 1985-01-08 | 1988-03-01 | Smithkline Beckman Corporation | 1-substituted-2-mercapto benzimidazole compounds and intermediates |
-
1969
- 1969-05-05 BE BE732508D patent/BE732508A/xx unknown
- 1969-05-07 DE DE19691923336 patent/DE1923336A1/de active Pending
- 1969-05-07 NL NL6906963A patent/NL6906963A/xx unknown
- 1969-05-07 GB GB2320269A patent/GB1217138A/en not_active Expired
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0064830A3 (en) * | 1981-04-29 | 1983-08-10 | Pfizer Limited | Pharmaceutical compositions for treating nail infections |
Also Published As
| Publication number | Publication date |
|---|---|
| NL6906963A (enrdf_load_stackoverflow) | 1969-11-11 |
| BE732508A (enrdf_load_stackoverflow) | 1969-10-16 |
| GB1217138A (en) | 1970-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE2711493C2 (enrdf_load_stackoverflow) | ||
| AT390878B (de) | Verfahren zur herstellung einer pharmazeutischen zubereitung unter einsatz eines analgetischen und antiinflammatorischen nichtsteroiden wirkstoffes | |
| DE69113386T2 (de) | Herstellung von Medikamenten zur Behandlung von Asthma, unter Verwendung von (S)-Alpha-Fluoromethyl-Histidin und dessen Estern. | |
| DE3786893T2 (de) | Piperidinderivat zur Schmerzbehandlung. | |
| DE19523502A1 (de) | Kappa-Opiatagonisten für entzündliche Darmerkrankungen | |
| DE69029732T2 (de) | Bivalente metallsalze von indomethacin | |
| DE1695837B2 (de) | Stickstoffheterocyclen enthaltende Di- und Triphenylpropylpiperazine, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel | |
| DE69721756T2 (de) | Paroxetine zur behandlung von depression | |
| EP0761650A1 (de) | Thermostabile und lagerfähige Kristallmodifikation von N-Methyl-N-((1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)-ethyl)-2,2-diphenyl-acetamid und Verfahren zu dessen Herstellung | |
| DE2359128A1 (de) | Arzneimittel auf basis von lisurid und dessen physiologisch vertraeglichen salzen | |
| DE1923336A1 (de) | Arzneimittel zur Behandlung von entzuendlichen Affektionen,Algien und Verletzungen | |
| DE2328060A1 (de) | Benzo- eckige klammer auf b eckige klammer zu -thiophenderivate und verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate | |
| DE3545201A1 (de) | Synergistische kombination von flupirtin und 4-acetamido-phenol | |
| DE2609746A1 (de) | Piperazinverbindungen sowie arzneimittel, die diese verbindungen enthalten | |
| DE2951912A1 (de) | Neues verfahren zur herstellung von piperidyl-indol-derivaten, hiernach erhaltene neue verbindung und deren salze, ihre anwendung als arzneimittel und die sie enthaltenden pharmazeutischen zusammensetzungen | |
| DE3608726A1 (de) | Verwendung aminosubstituierter benzoesaeuren als heilmittel gegen diarrhoe und arzneimittel auf basis dieser verbindungen | |
| DE2318784A1 (de) | N-(2,4-dihydroxybenzoyl)-4-aminosalizylsaeure | |
| DE69426317T2 (de) | Verwendung von Beta-Naphthochinonderivaten zur Hemmung von Blutplättchen-Aggregation | |
| DE2221281C3 (de) | Pharmazeutische Zubereitungen mit entzündungshemmender und analgetischer Wirkung | |
| DE2544100A1 (de) | Arzneimittel mit einem gehalt an 2-naphthyl-buttersaeurederivaten | |
| DE3005359A1 (de) | O-alkoxycarbonylphenyl-ester der flufenaminsaeure, verfahren zu deren herstellung und diese enthaltende arzneimittel | |
| DE19849650A1 (de) | Kappa-Opiatagonisten für die Behandlung des Irritable Bowel Syndroms (IBS) | |
| DE2935329A1 (de) | 1-methyl-piperidin-4-ol-ester, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel | |
| DE2146383C (de) | Oral verabreichbares Arzneimittel fur den rheumatischen Formenkreis | |
| DE1923337A1 (de) | 1-(p-Methotyphenyl)-2-methylbenzimidazol |